Marinus Pharmaceuticals, Inc. (MRNS)
- Previous Close
1.3300 - Open
1.3700 - Bid 1.3300 x 1000
- Ask 1.3600 x 1000
- Day's Range
1.3300 - 1.4200 - 52 Week Range
1.1100 - 11.2600 - Volume
891,752 - Avg. Volume
2,016,204 - Market Cap (intraday)
74.161M - Beta (5Y Monthly) 1.14
- PE Ratio (TTM)
-- - EPS (TTM)
-2.6400 - Earnings Date Aug 8, 2024 - Aug 12, 2024
- Forward Dividend & Yield --
- Ex-Dividend Date --
- 1y Target Est
6.90
Marinus Pharmaceuticals, Inc., a pharmaceutical company, focuses on development and commercialization of therapeutic products for patients suffering from rare genetic epilepsies and other seizure disorders. It offers ZTALMY (ganaxolone), an oral suspension for the treatment of seizures associated with cyclin-dependent kinase-like 5 deficiency disorder for adult and pediatric patient populations in acute and chronic care, and in-patient and self-administered settings. The company's ZTALMY product candidate acts at synaptic and extrasynaptic GABAA receptors, a target for its anti-seizure, antidepressant, and anxiolytic potential. It is developing ganaxolone for treating genetic epilepsy disorders, such as PCDH19-related epilepsy, and tuberous sclerosis complex. Marinus Pharmaceuticals, Inc. has license agreement with Purdue Neuroscience Company and CyDex Pharmaceuticals, Inc.; and collaboration agreement with Orion Corporation and Tenacia Biotechnology (Shanghai) Co., Ltd. Marinus Pharmaceuticals, Inc. was incorporated in 2003 and is headquartered in Radnor, Pennsylvania.
marinuspharma.comRecent News: MRNS
Performance Overview: MRNS
Trailing total returns as of 5/13/2024, which may include dividends or other distributions. Benchmark is .
YTD Return
1-Year Return
3-Year Return
5-Year Return
Compare To: MRNS
Select to analyze similar companies using key performance metrics; select up to 4 stocks.
Statistics: MRNS
Valuation Measures
Market Cap
74.16M
Enterprise Value
36.27M
Trailing P/E
--
Forward P/E
--
PEG Ratio (5yr expected)
--
Price/Sales (ttm)
2.63
Price/Book (mrq)
--
Enterprise Value/Revenue
--
Enterprise Value/EBITDA
--
Financial Highlights
Profitability and Income Statement
Profit Margin
0.00%
Return on Assets (ttm)
-46.11%
Return on Equity (ttm)
-423.43%
Revenue (ttm)
28.29M
Net Income Avi to Common (ttm)
-145.34M
Diluted EPS (ttm)
-2.6400
Balance Sheet and Cash Flow
Total Cash (mrq)
113.25M
Total Debt/Equity (mrq)
--
Levered Free Cash Flow (ttm)
-63.64M
Research Analysis: MRNS
Company Insights: MRNS
MRNS does not have Company Insights